ALERT
-
PAVmed Inc. is a highly differentiated, multiproduct medical device
company employing a unique business model designed to advance products
from concept to commercialization much more rapidly and with
significantly less capital than the typical medical device company.
These shares
BROKE OUT Jan 10, 2018 soaring more than 20 %.
These shares hit a 52 week high of $13.07 last year .
Recently these shares have risen three fold from $2.50
to over $9.00. Pulling back and forming a solid base at $3.00 these
shares are poised to challenge the $9.00 level once again . We look for
a volume breakout from these levels setting our initial target
price at $9.00 then advancing once again testing the $13.07
level
Investor Presentation : A Must See Report
Fact Sheet -
Products And
Pipeline
Fierce Innovation Awards 2017 Recognizes PAVmed’s CarpX™ Device
for Technology Innovation
NEW YORK
Device designed to replace invasive carpal tunnel
surgery, addressing an estimated $1 billion market
opportunity
PAVmed Inc. (Nasdaq: PAVM, PAVMW),
a highly differentiated, multiproduct medical device company,
today announced that CarpX™, its minimally invasive device
designed to treat carpal tunnel syndrome was recognized as one
of four finalists in the Technology Innovation category of the
2017 Fierce Innovation Awards. CarpX is pictured above.
This press
release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171218005280/en/
(Photo: Business Wire)
“PAVmed is honored to have been
recognized for technology innovation by one of the leading
voices in the life sciences industry. I would like to thank
Fierce Life Sciences and its independent panel of judges for
choosing to showcase our CarpX device as an example of
outstanding innovation,” said Lishan Aklog, M.D., PAVmed’s
Chairman and Chief Executive Officer. “We believe this honor
validates our firm conviction that CarpX, the most commercially
and clinically exciting product in our pipeline, is poised to
revolutionize the treatment of carpal tunnel syndrome, a widely
prevalent condition that imposes a significant clinical and
economic burden on society.”
Recipients of the Fierce Innovation
Awards: Life Sciences Edition 2017, which are presented annually
by leading industry publisher Fierce Life Sciences, were
selected from hundreds of applications in five categories by an
expert panel of judges consisting of industry luminaries.
According to Fierce Life Sciences, the Awards “showcase
outstanding innovation that is driving improvements and
transforming the industry” and sought “the best companies with
the most potential to make an impact…” CarpX was selected as one
of four finalists in the Technology Innovation category where
applicants were specifically judged for “using innovative
technology solutions to better serve the industry and promote
innovation.”
David A. Kelly, M.D., Co-Director of
Plastic Surgery at the Center for Dermatology and Plastic
Surgery in Gilbert, Arizona commented, “I am not at all
surprised that PAVmed’s innovative CarpX device is being
recognized by industry leaders. I strongly believe that CarpX
will be a game-changer in the treatment of carpal tunnel
syndrome, providing patients with a much less invasive option
and significantly shorter recovery times than traditional open
carpal tunnel surgery. I eagerly await the opportunity to offer
this ground-breaking innovation to my patients suffering from
carpal tunnel syndrome.”
Carpal tunnel syndrome is the most
common cumulative trauma disorder, accounts for over half of all
occupational injuries in the U.S. and results in over $20
billion in annual workers’ compensation costs. The carpal tunnel
is an anatomic space in the wrist through which tendons and the
median nerve pass. Cumulative trauma from repetitive motion
(e.g., typing) leads to inflammation, scarring and compression
of the nerve, resulting in a syndrome of debilitating symptoms
in the hands. It is estimated to affect 2.5% of U.S. adults,
with 600,000 undergoing invasive carpal tunnel surgery each year
and many more choosing to defer surgery and suffer in silence.
Traditional carpal tunnel surgery involves making incisions at
the base on the hand through which the scarred ligament is cut
to relieve compression of the nerve. Recovery times vary but can
last many months.
CarpX is designed to closely mimic
the anatomic results of invasive carpal tunnel surgery, but to
do so much less invasively, using catheters, balloons,
radiofrequency energy and other established tools that have
contributed to percutaneous and minimally invasive revolutions
in the treatment of other conditions. The balloon catheter
device is designed to be inserted under the scarred ligament in
a minimally invasive fashion, while pushing the nerve and
tendons away. When activated, bipolar radiofrequency electrodes
precisely cut the ligament from the inside out in a matter of
seconds. The device design provides physicians with ongoing
feedback to optimize the safety and completeness of the
procedure.
The U.S. Food and Drug
Administration recently accepted CarpX’s 510(k) premarket
notification submission for substantive review. PAVmed expects
to receive initial comments early in 2018 and is targeting
clearance during the first half of 2018.
About PAVmed
PAVmed Inc. is a highly
differentiated, multiproduct medical device company employing a
unique business model designed to advance products from concept
to commercialization much more rapidly and with significantly
less capital than the typical medical device company. This
proprietary model enables PAVmed to pursue an expanding pipeline
strategy with a view to enhancing and accelerating value
creation. PAVmed’s diversified pipeline of products address
unmet clinical needs, have attractive regulatory pathways and
market opportunities and encompass a broad spectrum of clinical
areas including carpal tunnel syndrome (CarpX™), interventional
radiology (PortIO™ and NextCath™), pediatric ear infections (DisappEAR™)
medical infusions (NextFlo™ and NextCath™), and tissue ablation
and cardiovascular intervention (Caldus™). The Company intends
to further expand its pipeline through engagements with
clinician innovators and leading academic medical centers. For
further information, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes
forward-looking statements that involve risks and uncertainties.
Forward-looking statements are statements that are not
historical facts. Such forward-looking statements, based upon
the current beliefs and expectations of the Company’s
management, are subject to risks and uncertainties, which could
cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such
differences include, among other things, the uncertainties
inherent in research and development, including the cost and
time required advance our products to regulatory submission;
whether regulatory authorities will be satisfied with the design
of and results from our preclinical studies; whether and when
our products are cleared by regulatory authorities; market
acceptance of our products once cleared and commercialized; our
ability to raise additional funding and other competitive
developments. PAVmed has not yet received clearance from the FDA
or other regulatory body to market any of its products. New
risks and uncertainties may arise from time to time and are
difficult to predict. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our
control. For a further list and description of these and other
important risks and uncertainties that may affect our future
operations, see Part I, Item IA, “Risk Factors,” in our most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, as the same may be updated in Part II, Item
1A, “Risk Factors” in any Quarterly Reports on Form 10-Q filed
by us after our most recent Annual Report. We disclaim any
intention or obligation to publicly update or revise any
forward-looking statement to reflect any change in our
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the
likelihood that actual results will differ from those contained
in the forward-looking statements.
PAVmed Files 510(k) Submission with FDA for CarpX™ Device to Treat
Carpal Tunnel Syndrome
Designed to replace invasive surgery and shorten recovery
time; addresses an estimated $1 billion market opportunity
PAVmed Inc. (Nasdaq: PAVM, PAVMW),
a highly differentiated, multiproduct medical device company, today
announced that it has filed a 510(k) premarket notification
submission with the U.S. Food and Drug Administration (FDA) for its
CarpX™ minimally invasive device designed to treat carpal tunnel
syndrome.
“We are very excited to have reached
this most important milestone in PAVmed’s corporate history,” said
Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “CarpX
has become the most commercially promising and clinically exciting
product in our pipeline and we believe it will revolutionize the
treatment of carpal tunnel syndrome, a widely prevalent condition
that exacts a significant clinical and economic burden on society in
the U.S. and worldwide. Based on epidemiological and market research
data we estimate CarpX's addressable market opportunity to exceed $1
billion."
David A. Kelly, M.D., Co-Director of
Plastic Surgery at the Center for Dermatology and Plastic Surgery in
Gilbert, Arizona, concurred. “I have had the opportunity to use
PAVmed’s highly innovative CarpX device in pre-submission testing
and am very impressed with its performance. As a busy hand surgeon,
I strongly believe that CarpX will be a game-changer in the
treatment of carpal tunnel syndrome, providing patients with a much
less invasive option and significantly shorter recovery times than
traditional open carpal tunnel surgery.”
Carpal tunnel syndrome is the most
common cumulative trauma disorder. It accounts for over half of all
occupational injuries in the U.S. and over $20 billion in annual
workers’ compensation costs. The carpal tunnel is an anatomic space
in the wrist through which tendons and the median nerve pass.
Cumulative trauma from repetitive motion (e.g., typing) leads to
inflammation, scarring and compression of the nerve, resulting in a
syndrome of debilitating symptoms in the hands. It is estimated to
affect 2.5% of U.S. adults with 600,000 undergoing invasive carpal
tunnel surgery each year and many more choosing to defer surgery and
suffer in silence. Traditional carpal tunnel surgery involves making
incisions at the base on the hand through which the scarred ligament
is cut to relieve compression of the nerve. Recovery times vary but
can last many months.
“We designed CarpX to closely mimic the
anatomic results of traditional invasive carpal tunnel surgery but
to do so much less invasively, using catheters, balloons,
radiofrequency energy and other established tools that have
contributed to the percutaneous and minimally invasive revolutions
in the treatment of other conditions,” said Brian J. deGuzman, M.D.,
PAVmed’s Chief Medical Officer. “Our balloon catheter device is
designed to be inserted under the scarred ligament in a minimally
invasive fashion, while pushing the nerve and tendons away. When
activated, bipolar radiofrequency electrodes precisely cut the
ligament from the inside out in a matter of seconds. The device
design provides physicians with ongoing feedback to optimize the
safety and completeness of the procedure,” he added.
“As with all of our products, CarpX’s
development and regulatory testing were performed using our unique
business model focused on speed to market and capital efficiency. We
are proud to have achieved this milestone within a timeframe and
with capital expenditures to date that beat our model’s benchmarks,”
added Dr. Aklog. “We believe we have assembled a strong submission
and are targeting clearance in the first half of 2018. Upon
successful regulatory clearance, we anticipate an aggressive
commercialization strategy using well-established independent sales
channels targeting the appropriate physician specialties.”
“I eagerly await CarpX’s regulatory
clearance and the opportunity to offer this ground-breaking
innovation to my patients suffering from carpal tunnel syndrome,”
said Dr. Kelly.
About PAVmed
PAVmed Inc. is a highly differentiated,
multiproduct medical device company employing a unique business
model designed to advance products from concept to commercialization
much more rapidly and with significantly less capital than the
typical medical device company. This proprietary model enables
PAVmed to pursue an expanding pipeline strategy with a view to
enhancing and accelerating value creation. PAVmed’s diversified
pipeline of products address unmet clinical needs, have attractive
regulatory pathways and market opportunities and encompass a broad
spectrum of clinical areas including carpal tunnel syndrome (CarpX™),
interventional radiology (PortIO™ and NextCath™), pediatric ear
infections (DisappEAR™) medical infusions (NextFlo™ and NextCath™),
and tissue ablation and cardiovascular intervention (Caldus™). The
Company intends to further expand its pipeline through engagements
with clinician innovators and leading academic medical centers. For
further information, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes
forward-looking statements that involve risks and uncertainties.
Forward-looking statements are statements that are not historical
facts. Such forward-looking statements, based upon the current
beliefs and expectations of the Company’s management, are subject to
risks and uncertainties, which could cause actual results to differ
from the forward-looking statements. Risks and uncertainties that
may cause such differences include, among other things, the
uncertainties inherent in research and development, including the
cost and time required advance our products to regulatory
submission; whether regulatory authorities will be satisfied with
the design of and results from our preclinical studies; whether and
when our products are cleared by regulatory authorities; market
acceptance of our products once cleared and commercialized; our
ability to raise additional funding and other competitive
developments. PAVmed has not yet received clearance from the FDA or
other regulatory body to market any of its products. New risks and
uncertainties may arise from time to time and are difficult to
predict. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further
list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item IA, “Risk Factors,” in our most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, as the same
may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly
Reports on Form 10-Q filed by us after our most recent Annual
Report. We disclaim any intention or obligation to publicly update
or revise any forward-looking statement to reflect any change in our
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements.
Q3 Conference Call
PAVmed Inc. (NASDAQ:PAVM; PAVMW), a highly differentiated,
multi-product medical device company, today announced that the Company
will host a conference call on Thursday, November 16, 2017 at 4:30 p.m.
Eastern time. During this call Lishan Aklog, M.D., the Company’s
Chairman and Chief Executive Officer, will provide a business update
including an overview of the Company’s near-term milestones and growth
strategy. In addition, Dennis McGrath, the Company’s Chief Financial
Officer, will discuss third quarter 2017 financial results.o access the conference call, U.S.-based listeners should dial (888)
803-5993 and international listeners should dial (706) 634-5454. All
listeners should provide the following passcode: 8082249. Individuals
interested in listening to the live conference call via the internet may
do so by visiting the Company’s website at www.pavmed.com.
Following the conclusion of the conference call, a replay will be
available through November 22, 2017 and can be accessed by dialing (855)
859-2056 from within the U.S. or (404) 537-3406 from outside the U.S.
All listeners should provide passcode: 8082249. The webcast will be
available for a period of time on the Company’s website at www.pavmed.com.
PAVmed Reports Third Quarter 2017 Financial Results
NEW YORK
Conference call to be held November 16, 2017 at 4:30 p.m.
Eastern time
PAVmed Inc. (Nasdaq: PAVM, PAVMW),
a highly differentiated, multiproduct medical device company, today
announced financial results for the three and nine months ended
September 30, 2017 and provided a business update.
Management Commentary
“During this quarter and in recent
weeks, PAVmed has continued its inexorable march towards important
developmental, regulatory and commercialization milestones,” said
Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer.
“Last month we filed a pre-submission to
the U.S. Food and Drug Administration (FDA), as we now seek a de
novo classification for our PortIO™ Intraosseous
Infusion System. PortIO is an implantable vascular access device
designed to provide long-term access to the bone marrow cavity, for
the delivery of medications, fluids or other substances, eliminating
many of the shortcomings of existing devices, especially in patients
with poor veins. The pre-submission provides our proposal for
limited additional testing to support a longer, seven-day indication
which will cover the use of the device in most inpatient scenarios.
It includes a request for an in-person meeting with the FDA next
month. If we are successful in obtaining de novo classification
clearance, we plan to proceed with commercialization of the device
while using it as a predicate for longer, expanded indications
through the 510(k) pathway. Our initial commercialization strategy
will focus on independent distributors targeting key opinion leaders
and early adopters.”
Dr. Aklog added, “Our CarpX™ device
designed to treat carpal tunnel syndrome through a minimally
invasive approach, remains the most commercially promising and
clinically exciting lead product in our pipeline. We have weathered
some last-minute delays and are poised to complete testing and
submit this game-changing device to the FDA for 510(k) clearance
later this month. Upon successful regulatory clearance, we
anticipate an aggressive commercialization strategy using
well-established independent sales channels targeting the
appropriate physician specialties. We believe that CarpX will
provide an attractive alternative for the 600,000 patients a year
who undergo traditional carpal tunnel surgery in the U.S. in terms
of invasiveness, pain, recovery time, and cost effectiveness, as
well as the vast number of patients who choose to avoid surgery and
suffer in silence.”
“Our final lead product, DisappEAR, is
progressing well along its development path,” continued Dr. Aklog. “DisappEAR
is our resorbable, anti-microbial pediatric ear tube which utilizes
a propriety aqueous silk technology licensed from Tufts University
and two Harvard teaching hospitals. It is designed to provide a more
efficacious and patient-friendly alternative to traditional plastic
ear tubes that are inserted in over one million children annually.
We expect that DisappEAR will be ready for FDA submission in the
second half of 2018.”
“Finally, we strengthened our balance
sheet during the third quarter, raising $5.5 million from the sale
of senior secured notes, warrants, and convertible preferred stock,
providing us with the resources to advance our lead products towards
commercialization.”
Financial Results
Research and development expenses for
the three months ended September 30, 2017 were $704,866. General and
administrative expenses for the three months ended September 30,
2017 were $1,263,122.
PAVmed reported an operating loss for
the three months ended September 30, 2017 of $1,967,988 and a GAAP
net loss of $5,129,318. Included in the GAAP net loss were non-cash
charges totaling $2,799,188 related to a change in the fair value of
Series A warrant liability and a related change in fair value of a
Series A Convertible Preferred Stock conversion option embedded
derivative liability. Also included was a non-cash charge for
stock-based compensation expense of $272,301 and depreciation
expense of $1,802.
For the three months ended September 30,
2017, GAAP net loss attributable to common stockholders was
$5,370,313, or $0.40 per common share. As illustrated below and for
the purpose of helping the reader to understand the effect of
derivative accounting for non-cash income and expenses on the
Company’s financial results, the Company reported a non-GAAP
adjusted loss for the three months ended September 30, 2017 of
$1,693,885, or $0.13 per common share.
Research and development expenses for
the nine months ended September 30, 2017 were $2,063,319. General
and administrative expenses for the nine months ended September 30,
2017 were $4,082,366.
PAVmed reported an operating loss for
the nine months ended September 30, 2017 of $6,145,685 and a GAAP
net loss of $10,389,113. Included in the GAAP net loss were non-cash
charges totaling $3,881,286 related to the issuance of Series A
Preferred Stock Units, a change in the fair value of Series A
warrant liability and a related change in fair value of a Series A
Convertible Preferred stock conversion option embedded derivative
liability. Also included was a non-cash charge for stock-based
compensation expense of $799,281 and depreciation expense of $5,307.
For the nine months ended September 30,
2017, GAAP net loss attributable to common stockholders was
$10,707,819, or $0.80 per common share. The Company reported a
non-GAAP adjusted loss for the nine months ended September 30, 2017
of $5,341,097, or $0.40 per common share, as illustrated below.
PAVmed had cash and cash equivalents of
$3,111,456 as of September 30, 2017, compared with $585,680 as of
December 31, 2016.
The unaudited financial results for the
three and nine months ended September 30, 2017 as reported to the
SEC on Form 10-Q can be obtained at www.pavmed.com or www.sec.gov.
Non-GAAP Measures
To supplement our unaudited financial
results presented in accordance with U.S. generally accepted
accounting principles (GAAP) in our Quarterly Report on Form 10-Q,
management provides certain non-GAAP financial measures of the
Company's financial results. These non-GAAP financial measures
include net loss before interest, taxes, depreciation and
amortization (EBITDA) and non-GAAP Adjusted Loss, which further
adjusts EBITDA for stock-based compensation expense, loss on the
issuance of the Series A Preferred Stock Units, the change in fair
value of the Series A Warrant liability and the change in fair value
of the Series A Convertible Preferred Stock conversion option
embedded derivative liability. The foregoing non-GAAP financial
measures of EBITDA and non-GAAP Adjusted Loss are not recognized
terms under U.S. GAAP.
Non-GAAP financial measures are
presented with the intent of providing greater transparency to
information used by us in our financial performance analysis and
operational decision-making. We believe these non-GAAP financial
measures provide meaningful information to assist investors,
shareholders and other readers of our unaudited financial statements
in making comparisons to our historical financial results and
analyzing the underlying performance of our results of operations.
These non-GAAP financial measures are not intended to be, and should
not be, a substitute for, considered superior to, considered
separately from or as an alternative to, the most directly
comparable GAAP financial measures.
Non-GAAP financial measures are provided
to enhance readers’ overall understanding of our current financial
results and to provide further information for comparative purposes.
Management believes the non-GAAP financial measures provide useful
information to management and investors by isolating certain
expenses, gains and losses that may not be indicative of our core
operating results and business outlook. Specifically, the non-GAAP
financial measures include non-GAAP adjusted loss and its
presentation is intended to help the reader understand the effect of
the loss on the issuance of the Series A Preferred Stock Units and
the corresponding derivative accounting for non-cash charges on
financial performance. In addition, management believes non-GAAP
financial measures enhance the comparability of results against
prior periods.
A reconciliation to the most directly
comparable GAAP measure of all non-GAAP financial measures included
in this press release for the three and nine months ended September
30, 2017 and 2016 is as follows:
|
|
|
|
|
Three Months Ended September 30, |
|
|
|
Nine Months Ended September 30, |
|
|
|
|
|
2017 |
|
2016 |
|
|
|
2017 |
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share, basic and diluted |
|
|
|
($0.40) |
|
($0.14) |
|
|
|
($0.80) |
|
($0.31) |
Net loss attributable to common stockholders |
|
|
|
(5,370,313) |
|
(1,928,722) |
|
|
|
(10,707,819) |
|
(3,940,337) |
Preferred Stock dividends |
|
|
|
240,995 |
|
- |
|
|
|
$318,706 |
|
|
|
Net loss as
reported |
|
|
|
(5,129,318) |
|
(1,928,722) |
|
|
|
(10,389,113) |
|
(3,940,337) |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
expense1 |
|
|
|
1,802 |
|
1,478 |
|
|
|
5,307 |
|
2,315 |
|
Interest expense,
net |
|
|
|
362,142 |
|
- |
|
|
|
362,142 |
|
- |
|
Income
tax (benefit) expense |
|
|
|
- |
|
- |
|
|
|
- |
|
- |
EBITDA |
|
|
|
(4,765,374) |
|
(1,927,244) |
|
|
|
(10,021,664) |
|
(3,938,022) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other non-cash expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation expense2 |
|
|
|
272,301 |
|
322,985 |
|
|
|
799,281 |
|
499,628 |
|
Loss from
issuance of Preferred Stock Units3 |
|
|
|
- |
|
- |
|
|
|
3,124,285 |
|
- |
|
Change in fair value of Series A Warrant Liabiity3 |
2,215,671 |
|
- |
|
|
|
680,851 |
|
- |
|
Change in
fair value of Series A Preferred Stock
conversion option embedded derivative liabiity3
|
|
|
|
583,517 |
|
- |
|
|
|
76,150 |
|
- |
Non-GAAP adjusted (loss) |
|
|
|
(1,693,885) |
|
(1,604,259) |
|
|
|
(5,341,097) |
|
(3,438,394) |
|
Basic and Diluted
shares outstanding |
|
|
|
13,332,629 |
|
13,310,000 |
|
|
|
13,331,585 |
|
12,855,714 |
|
Non-GAAP adjusted
(loss) income per share |
|
|
|
($0.13) |
|
($0.12) |
|
|
|
($0.40) |
|
($0.27) |
1 |
|
|
Included in
general and administrative expenses in the financial
statements |
|
|
|
|
2 |
|
|
The three
and nine months ended September 30, 2017 includes $241,401
and $707,588, respectively, of stock-based
compensation expense reported as general and administrative
expenses and $30,900 and $91,693, respectively,
reported as research and development expense. The three and
nine months ended September 30, 2016 includes
$292,085 and $447,233, respectively, of stock-based
compensation expense reported as general and
administrative expenses and $30,900 and $52,396,
respectively, reported as research and development expense.
|
|
|
|
|
3 |
|
|
Included in other
income and expenses in the financial statements. |
|
|
|
|
Conference Call and Webcast
The Company will hold a conference call
and webcast on November 16, 2017 at 4:30 p.m. Eastern time. During
this call, Dr. Aklog will provide a business update, including an
overview of the Company’s near-term milestones and growth strategy.
In addition, Dennis McGrath, the Company’s Chief Financial Officer,
will discuss third quarter 2017 financial results.
To access the conference call,
U.S.-based participants should dial (888) 803-5993 and international
participants should dial (706) 634-5454. All participants should
provide the following pascode: 8082249. Individuals interested in
listening to the live conference call via the Internet may do so by
visiting the Company’s website at www.pavmed.com.
Following the conclusion of the
conference call, a replay will be available through November 22,
2017 and can be accessed by dialing (855) 859-2056 from within the
U.S., or (404) 537-3406 from outside the U.S. All listeners should
provide passcode: 8082249. The webcast will be available for 90 days
on the Company’s website at www.pavmed.com.
About PAVmed
PAVmed Inc. is a highly differentiated,
multiproduct medical device company employing a unique business
model designed to advance products from concept to commercialization
much more rapidly and with significantly less capital than the
typical medical device company. This proprietary model enables
PAVmed to pursue an expanding pipeline strategy with a view to
enhancing and accelerating value creation. PAVmed’s diversified
pipeline of products address unmet clinical needs, have attractive
regulatory pathways and market opportunities and encompass a broad
spectrum of clinical areas including carpal tunnel syndrome (CarpX™),
interventional radiology (PortIO™ and NextCath™), pediatric ear
infections (DisappEAR™) medical infusions (NextFlo™ and NextCath™),
and tissue ablation and cardiovascular intervention (Caldus™). The
Company intends to further expand its pipeline through engagements
with clinician innovators and leading academic medical centers. For
further information, please visit www.pavmed.com.
About BioTechReporter.net :
BioTechReporter.net is
a subsidiary
of Target Publishing Inc, and is a leading publisher of
todays market and investment news, commentary,
proprietary research and videos from seasoned
journalists, analysts and contributors covering the
financial markets and global economies. Leveraging our
extensive distribution network and social media
presence, we have cultivated
a valuable audieXnce of
engaged market enthusiasts, which in turn
delivers a variety of unique opportunities for industry
partnerships, corporate communications, market exposure
and investment. We
are paid cash compensation by the company only for the distribution of this report.
A complete disclaimer can be viewed HERE
|